#pspjournal kết quả tìm kiếm
New in #PSPjournal: First published PBPK model of a Claudin 18.2-targeting ADC qualified with clinical data using PK-Sim. Read more: bit.ly/4oocz7G #ASCPTjournals #ClinicalPharmacology
Get to know #PSPjournal Editor in Training, João Abrantes, in the latest issue of #CPTjournal: bit.ly/46lFst6
Meet the #ASCPTjournals' 2025-2026 Editors-in-Training! Welcome to the ASCPT Journal Family. #CPTjournal #PSPjournal #CTSjournal
#ASCPTjournals can't thank João Abrantes, Jiawei Zhou, Daisy Zhu, Lanfranco Pellesi, Matthijs van Hoogdalem, and Allison Dunn for their strong contributions to #PSPjournal, #CTSjournal, and #CPTjournal during their time as Editors-in-Training!
Showcasing the potential of IVIVC/R models, including PBBM, offering insights from academia, industry, and others on future opportunities, challenges, regulatory perspectives, and competency gaps. Read here: bit.ly/3JxHH4W #PSPjournal #ASCPTjournals #ClinicalPharmacology
New in CPT:PSP! PopPK/PD modeling of ibrutinib ± venetoclax in TN & R/R CLL shows dose de-escalation preserves efficacy, PFS, deep MRD & lowers hypertension. Model supports individualized dosing. ascpt.onlinelibrary.wiley.com/doi/10.1002/ps… #PSPjournal #ASCPTjournals #ModelInformedDrugDevelopment
In this original research article from #PSPjournal, the concePTION project reports out about a recent study about predicting drug transfer into human milk: bit.ly/4qc8R22
A new PBPK model for rosuvastatin predicts PK variability across genetics, ethnicity, pregnancy & DDIs—integrating RSV-lactone interconversion & hepatic distribution. Read more: bit.ly/4g3SiAq #PSPjournal #ASCPTjournals #ClinicalPharmacology
Now in its 20th edition, the Basel M&S Seminar has become a key platform for advancing Pharmacometrics and related disciplines. This perspective article reviews its history, impact, and future directions. Read more in CPT:PSP: bit.ly/4lSmAaF #PSPjournal #ASCPTjournals
Check out this article from #PSPjournal for a look at a framework that offers a robust alternative to the misapplied standard survival models for analyzing competing risks in interval-censored longitudinal data. bit.ly/4oykqz1
Are we ready for the next pandemic? This mini-review from #PSPjournal discusses viral dynamic models to find the answer. bit.ly/3HRW5EE
I’m thrilled to share our new paper on PBPK modelling of dose adjustments of ATV/r to overcome DDI with rifampicin during pregnancy, published in #PSPJournal. You can read it here: ascpt.onlinelibrary.wiley.com/doi/10.1002/ps… #ASCPTJournalFamily
This study on ligelizumab for CSU shows how a model-based approach guided dose selection, trial design, pediatric extrapolation & labeling decisions—optimizing outcomes & patient access. Read more: bit.ly/3V2jeah #PSPjournal #ASCPTjournals #ClinicalPharmacology
By applying #deeplearning to synthetic PK, we showed that it's possible to generate a "specialist" numerical approximator for the domain of PK profiles, with benefits compared to the "generalist" approximators used in Noncompartmental Analysis. #PSPjournal doi.org/10.1002/psp4.1…
Friendly Reminder! Does your research involve innovative MBMA methodologies and/or applications? Then submit it for the Model-Based Meta-Analysis special collection of #PSPjournal. Submissions are due by July 31, 2025.bit.ly/4gCTOJa
I am excited to share that our latest research, "Preclinical side effect prediction through pathway engineering of protein interaction network models," has been published in CPT (#PSPJournal). Check out the full article here: lnkd.in/gjsRJUiz (#ASCPTJournalFamily!)
Showcasing the potential of IVIVC/R models, including PBBM, offering insights from academia, industry, and others on future opportunities, challenges, regulatory perspectives, and competency gaps. Read here: bit.ly/3JxHH4W #PSPjournal #ASCPTjournals #ClinicalPharmacology
New in CPT:PSP! PopPK/PD modeling of ibrutinib ± venetoclax in TN & R/R CLL shows dose de-escalation preserves efficacy, PFS, deep MRD & lowers hypertension. Model supports individualized dosing. ascpt.onlinelibrary.wiley.com/doi/10.1002/ps… #PSPjournal #ASCPTjournals #ModelInformedDrugDevelopment
Check out this article from #PSPjournal for a look at a framework that offers a robust alternative to the misapplied standard survival models for analyzing competing risks in interval-censored longitudinal data. bit.ly/4oykqz1
In this original research article from #PSPjournal, the concePTION project reports out about a recent study about predicting drug transfer into human milk: bit.ly/4qc8R22
Get to know #PSPjournal Editor in Training, João Abrantes, in the latest issue of #CPTjournal: bit.ly/46lFst6
Are we ready for the next pandemic? This mini-review from #PSPjournal discusses viral dynamic models to find the answer. bit.ly/3HRW5EE
Meet the #ASCPTjournals' 2025-2026 Editors-in-Training! Welcome to the ASCPT Journal Family. #CPTjournal #PSPjournal #CTSjournal
This study on ligelizumab for CSU shows how a model-based approach guided dose selection, trial design, pediatric extrapolation & labeling decisions—optimizing outcomes & patient access. Read more: bit.ly/3V2jeah #PSPjournal #ASCPTjournals #ClinicalPharmacology
#ASCPTjournals can't thank João Abrantes, Jiawei Zhou, Daisy Zhu, Lanfranco Pellesi, Matthijs van Hoogdalem, and Allison Dunn for their strong contributions to #PSPjournal, #CTSjournal, and #CPTjournal during their time as Editors-in-Training!
A new PBPK model for rosuvastatin predicts PK variability across genetics, ethnicity, pregnancy & DDIs—integrating RSV-lactone interconversion & hepatic distribution. Read more: bit.ly/4g3SiAq #PSPjournal #ASCPTjournals #ClinicalPharmacology
Now in its 20th edition, the Basel M&S Seminar has become a key platform for advancing Pharmacometrics and related disciplines. This perspective article reviews its history, impact, and future directions. Read more in CPT:PSP: bit.ly/4lSmAaF #PSPjournal #ASCPTjournals
New in #PSPjournal: First published PBPK model of a Claudin 18.2-targeting ADC qualified with clinical data using PK-Sim. Read more: bit.ly/4oocz7G #ASCPTjournals #ClinicalPharmacology
This new publication shows that a pharmacometric approach outperforms traditional statistical methods in planning a Phase 2 multi-regional trials for an anti-psoriatic drug: bit.ly/4mrryfU #PSPjournal #ASCPTjournals #ClinicalPharmacology
van Os et al. used multi-label classification to guide individualized vancomycin PK model selection for a priori MIPD. Read more: bit.ly/3JmqbAk #PSPjournal #ASCPTjournals #ClinicalPharmacology
Part 2 of the AZD8233 MIDD journey is out! After accelerating FIH to Phase 2 by 6 months (see Part 1), the authors now reveal Phase 2 results — predictions were spot on. See how Phase 3 was shaped: bit.ly/461RwQb #PSPjournal #ASCPTjournals #ClinicalPharmacology
In this article from the most recent issue of #PSPjournal, read how model-based analysis was used to inform the design of early clinical trials of Anti-Amyloid Beta therapies in Alzheimer's Disease: bit.ly/45Fiaz8
New in #PSPjournal: A TGI-OS model for HR+/HER2− breast cancer was developed using shared clinical trial data from Vivli. Read more: bit.ly/4lW1Uj0 #ASCPTjournals #ClinicalPharmacology
New in #PSPjournal: First published PBPK model of a Claudin 18.2-targeting ADC qualified with clinical data using PK-Sim. Read more: bit.ly/4oocz7G #ASCPTjournals #ClinicalPharmacology
Get to know #PSPjournal Editor in Training, João Abrantes, in the latest issue of #CPTjournal: bit.ly/46lFst6
New in CPT:PSP! PopPK/PD modeling of ibrutinib ± venetoclax in TN & R/R CLL shows dose de-escalation preserves efficacy, PFS, deep MRD & lowers hypertension. Model supports individualized dosing. ascpt.onlinelibrary.wiley.com/doi/10.1002/ps… #PSPjournal #ASCPTjournals #ModelInformedDrugDevelopment
Now in its 20th edition, the Basel M&S Seminar has become a key platform for advancing Pharmacometrics and related disciplines. This perspective article reviews its history, impact, and future directions. Read more in CPT:PSP: bit.ly/4lSmAaF #PSPjournal #ASCPTjournals
Showcasing the potential of IVIVC/R models, including PBBM, offering insights from academia, industry, and others on future opportunities, challenges, regulatory perspectives, and competency gaps. Read here: bit.ly/3JxHH4W #PSPjournal #ASCPTjournals #ClinicalPharmacology
Check out this article from #PSPjournal for a look at a framework that offers a robust alternative to the misapplied standard survival models for analyzing competing risks in interval-censored longitudinal data. bit.ly/4oykqz1
By applying #deeplearning to synthetic PK, we showed that it's possible to generate a "specialist" numerical approximator for the domain of PK profiles, with benefits compared to the "generalist" approximators used in Noncompartmental Analysis. #PSPjournal doi.org/10.1002/psp4.1…
Get to know #PSPjournal Editor-in-Training, Jiawei Zhou in this month's #CPTjournal #IamASCPT: bit.ly/4lId1LL
📅 DEADLINE ALERT! Submissions for the #PSPjournal Model-Based Meta-Analysis (MBMA) special collection must be in by June 15! bit.ly/4gCTOJa
Are we ready for the next pandemic? This mini-review from #PSPjournal discusses viral dynamic models to find the answer. bit.ly/3HRW5EE
Friendly Reminder! Does your research involve innovative MBMA methodologies and/or applications? Then submit it for the Model-Based Meta-Analysis special collection of #PSPjournal. Submissions are due by July 31, 2025.bit.ly/4gCTOJa
🔬 Exciting new tutorial on accelerating PBPK/PD modeling workflows! Check it out from #PSPjournal: bit.ly/3ZiMJY1
📢 Call for Papers: #PSPjournal seeks submissions on model-based innovations for pediatric rare diseases. Share your research on pharmacometrics, systems pharmacology, and modeling approaches. Deadline: May 15, 2025. #RareDiseases #Pharmacometrics #MIDD bit.ly/4eO5d8k
Deadline Approaching! The #PSPjournal "Pediatric Rare Disease" themed Call for Papers closes next week (May 15)! bit.ly/4eO5d8k
In this article from the most recent issue of #PSPjournal, read how model-based analysis was used to inform the design of early clinical trials of Anti-Amyloid Beta therapies in Alzheimer's Disease: bit.ly/45Fiaz8
Something went wrong.
Something went wrong.
United States Trends
- 1. Penn State 19.2K posts
- 2. Mendoza 16.1K posts
- 3. Gus Johnson 4,376 posts
- 4. #iufb 3,403 posts
- 5. Omar Cooper 6,143 posts
- 6. $SSHIB 1,683 posts
- 7. Sunderland 143K posts
- 8. Jim Knowles N/A
- 9. James Franklin 6,493 posts
- 10. Texas Tech 12.3K posts
- 11. Sayin 60.8K posts
- 12. Happy Valley 1,526 posts
- 13. Arsenal 241K posts
- 14. WHAT A CATCH 10.2K posts
- 15. Charlie Becker N/A
- 16. Jeremiah Smith 2,369 posts
- 17. St. John 7,745 posts
- 18. CATCH OF THE YEAR 3,585 posts
- 19. #GoDawgs 4,552 posts
- 20. #WeAre 1,101 posts